What Is Kopexil?
Kopexil (INCI name: Diaminopyrimidine Oxide, CAS 74638-76-9) is a synthetic compound from the pyrimidine family, widely used in hair care products as a conditioning and anti‑hair loss agent. Also known by trade names such as Aminexil® and Mexoryl SAG, Kopexil is structurally similar to minoxidil - the FDA‑approved gold‑standard hair growth treatment - while being classified as a cosmetic raw material rather than a pharmaceutical drug [5]. This distinction allows formulators to create effective anti‑hair loss products within the cosmetic regulatory framework, without the stricter requirements associated with drug approvals.
Kopexil is commonly incorporated into a wide range of hair products, including shampoos, conditioners, serums, tonics, and scalp lotions. It functions primarily as a hair conditioning and skin conditioning agent, maintaining the scalp in good condition while addressing the underlying mechanisms of hair loss [4].
How Kopexil Works: Mechanism of Action
Kopexil promotes hair growth and prevents premature hair loss through a multi‑target approach:
- 5α‑Reductase Inhibition: Kopexil inhibits the enzyme 5α‑reductase, which converts testosterone into dihydrotestosterone (DHT) - a potent androgen that accelerates hair follicle miniaturization in androgenetic alopecia (AGA). By reducing DHT levels at the follicular level, Kopexil helps maintain healthy hair growth.
- Potassium Channel Activation: Similar to minoxidil, Kopexil may activate potassium channels in hair follicle cells, leading to vasodilation and improved blood flow to the scalp. This enhanced microcirculation delivers more oxygen and essential nutrients directly to the hair roots.
- Anagen Phase Prolongation: By extending the anagen (active growth) phase of the hair cycle and delaying the transition to telogen (resting) phase, Kopexil helps maintain greater hair density over time.
- Collagen Softening: Rigidification of collagen around hair follicles can contribute to follicular fibrosis and progressive hair loss. Kopexil helps soften perifollicular collagen, preserving the structural integrity of hair follicles and allowing them to function optimally.
Key Benefits of Kopexil in Hair Care
1. Superior Hair Growth Promotion Compared to Minoxidil
The most compelling evidence for Kopexil comes from a 2024 in vivo comparative study published in BioImpacts (PubMed‑indexed, peer‑reviewed) [1]. Researchers compared the effects of a 5% hydro‑alcoholic solution containing Kopexil against minoxidil in a 28‑day animal study.
Key findings [1]:
- The Kopexil group demonstrated significant increases in hair weight, follicle count, percentage of anagen hair, and overall hair growth compared to the minoxidil group.
- Western blot analysis revealed higher expression levels of hair growth‑promoting factors (including VEGF and HGF) in the Kopexil‑treated group compared to both the minoxidil and control groups.
- No statistically significant differences in liver and kidney weights or morphological variations were observed in toxicity tests across all groups, indicating a favorable safety profile.
The study concluded that "the 5% (w/v) hydro‑alcoholic solution containing kopexil proved to be an effective hair growth stimulator, influencing various factors. Its daily use can be considered a suitable treatment method for stimulating hair growth, given its improved effectiveness and ease of use for patients" [1].
This head‑to‑head comparison positions Kopexil as a promising alternative to minoxidil for cosmetic hair growth applications.
2. Proven Clinical Efficacy: 89% Hair Loss Reduction
Beyond animal studies, Kopexil has demonstrated real‑world clinical efficacy. A large, international observational real‑life study evaluated AC5 - a formulation containing 2,4‑Diamino‑Pyrimidine‑N‑Oxyde (Kopexil), arginine, piroctone olamine, and Vichy mineralizing water - in 527 subjects with mild androgenetic alopecia [2].
Key results after 3 months [2]:
| Metric | Result |
|---|---|
| Hair loss reduction (all subjects) | 89.0% |
| Hair loss reduction (women) | 92.5% |
| Hair loss reduction (men) | 83.8% |
| Subject satisfaction (0–10 scale) | 7.9 ± 1.7 |
| Tolerance rated good/very good | 98.6% |
The study concluded that AC5 "reduces mild AGA in both men and women with a pleasant texture. AC5 was well tolerated and highly appreciated" [2]. These results provide strong clinical validation for Kopexil's efficacy in real‑world use.
3. Superior Skin Permeation for Enhanced Bioavailability
A 2026 study published in Pharmaceutical Sciences (peer‑reviewed) investigated the physicochemical characteristics, storage stability, and skin permeation behavior of Kopexil in direct comparison with minoxidil [3].
The study employed validated HPLC methodology and Franz diffusion cells to quantify permeated drug levels. The results demonstrated enhanced skin permeation of Kopexil compared to minoxidil, suggesting a potential advantage in topical alopecia treatment [3]. Stability testing revealed t90% values of 39–50 months for Kopexil formulations under different storage conditions - indicating excellent shelf‑life stability [3].
For formulators, this means Kopexil not only performs effectively but also remains stable over time, reducing the risk of product degradation during storage.
4. Excellent Safety Profile and Regulatory Compliance
Kopexil has been thoroughly evaluated for safety in cosmetic applications. According to the Cosmetic Ingredient Review (CIR) 2023 Final Report, the compound is classified as safe for use as a hair conditioning and skin conditioning agent [4].
Regulatory status [4][5]:
| Region | Restriction |
|---|---|
| EU | Annex III, maximum 1.5% in leave‑on hair products (Regulation (EC) No 1223/2009) |
| China | Table 3: restricted ingredient, maximum 1.5% in hair products (CSVT 2015) |
| US | Not FDA‑approved as a drug; permissible in cosmetics at appropriate concentrations |
The animal toxicity study published in BioImpacts (2024) further confirmed the safety of Kopexil, reporting no statistically significant differences in liver and kidney weights or noticeable morphological variations in toxicity tests across treatment groups [1].
Unlike minoxidil, which can have systemic side effects including effects on blood pressure, Kopexil offers a better safety profile for cosmetic use, with no reported systemic effects at recommended concentrations.
5. Versatile Formulation Compatibility
Kopexil powder is remarkably versatile and can be incorporated into a wide range of hair care product types:
- Leave‑on products: Serums, tonics, scalp lotions (0.5–1.5%)
- Rinse‑off products: Shampoos, conditioners (0.5–1.0%)
- Styling products: Gels, sprays, mists
Kopexil is compatible with various active ingredients commonly used in anti‑hair loss formulations, including piroctone olamine, caffeine, biotin, and botanical extracts. For enhanced skin penetration, encapsulation technologies such as niosomes have been shown to further improve delivery efficiency.
It is soluble in water‑based formulations, making it easy to incorporate into aqueous systems without requiring complex solubilization techniques. This flexibility allows formulators to create elegant, stable products that deliver consistent results.
Why Choose Kopexil Powder for Your Hair Care Formulations?
High‑purity Kopexil (Diaminopyrimidine Oxide) powder offers significant advantages for cosmetic formulators and brand owners:
| Feature | Benefit |
|---|---|
| Scientifically validated efficacy | 89% hair loss reduction in clinical study [2]; outperformed minoxidil in animal study [1] |
| Superior skin penetration | Enhanced permeation compared to minoxidil for better bioavailability [3] |
| Excellent safety profile | CIR‑approved [4]; no organ toxicity observed [1] |
| Regulatory compliance | Permitted up to 1.5% in the EU and China [4][5] |
| Proven stability | t90% values of 39–50 months under ICH conditions [3] |
| Versatile application | Suitable for shampoos, serums, tonics, and conditioners |
| Clean label | Single, recognizable active ingredient with strong consumer recognition (Aminexil®) |
When sourcing Kopexil powder, select suppliers who provide third‑party testing documentation for purity (≥98% by HPLC), heavy metals, residual solvents, and microbiological contaminants, along with a Certificate of Analysis for each batch.
Formulation Guidelines
For optimal results, Kopexil is typically used at the following concentrations [5]:
- Hair serums and leave‑on tonics: 0.5–1.5% (EU maximum: 1.5%)
- Conditioners (leave‑on): 0.5–1.5%
- Hair gels and sprays: 0.5–1.5%
- Shampoos (rinse‑off): 0.5–1.0%
- Scalp treatments: 0.5–1.5%
Kopexil is soluble in water and can be added during the aqueous phase of formulation processing. It is compatible with a wide pH range (typically 4.0–7.0) and remains stable under standard manufacturing conditions.
Conclusion
Kopexil (Diaminopyrimidine Oxide) is a scientifically validated, multifunctional hair care ingredient that directly addresses one of the most common consumer concerns: hair loss and thinning. With a well‑established mechanism of action targeting 5α‑reductase inhibition, potassium channel activation, anagen phase prolongation, and collagen softening, Kopexil provides a comprehensive approach to maintaining healthy hair.
Clinical and preclinical evidence strongly support its efficacy - outperforming minoxidil in animal studies, demonstrating an 89% hair loss reduction rate in human subjects, and exhibiting superior skin permeation characteristics compared to the pharmaceutical standard. Furthermore, its favorable safety profile, regulatory approval in major markets, and excellent formulation stability make it an ideal choice for cosmetic formulators seeking to develop effective, science‑driven hair care products.
Whether you are formulating a premium anti‑hair loss serum, a daily‑use conditioner, or a scalp treatment tonic, high‑purity Kopexil powder delivers measurable results that consumers can see and feel - all within the cosmetic regulatory framework.